Trial Profile
A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2452473/tadalafil (Primary) ; Tadalafil
- Indications Erectile dysfunction
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 06 May 2015 Results (effects on lean body mass) published in Transition Therapeutics media release; Transition Therapeutics has licensed the rights for TT701 from Eli LIlly.
- 16 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 16 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.